Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,246,408
  • Shares Outstanding, K 108,210
  • Annual Sales, $ 5,872 M
  • Annual Income, $ 1,199 M
  • 36-Month Beta 1.36
  • Price/Sales 6.97
  • Price/Cash Flow 23.86
  • Price/Book 5.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 5.10
  • Number of Estimates 1
  • High Estimate 5.10
  • Low Estimate 5.10
  • Prior Year 4.46
  • Growth Rate Est. (year over year) +14.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
331.54 +14.97%
on 11/20/18
396.32 -3.82%
on 12/04/18
+43.88 (+13.01%)
since 11/14/18
3-Month
327.58 +16.36%
on 10/29/18
410.00 -7.03%
on 10/01/18
-11.00 (-2.80%)
since 09/14/18
52-Week
281.89 +35.22%
on 05/09/18
416.49 -8.48%
on 08/30/18
-1.95 (-0.51%)
since 12/14/17

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

IBB : 101.93 (-1.89%)
GILD : 65.57 (-2.64%)
REGN : 381.17 (+0.70%)
ALXN : 109.43 (-2.67%)
BIIB : 314.55 (-1.75%)
4 Biotech Stocks Investors Can Add to Their Portfolio in 2019

Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.

GILD : 65.57 (-2.64%)
REGN : 381.17 (+0.70%)
BIIB : 314.55 (-1.75%)
ALXN : 109.43 (-2.67%)
Why Is Regeneron (REGN) Up 2.4% Since Last Earnings Report?

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

REGN : 381.17 (+0.70%)
Regeneron Pharm Rises 1.96% on Heavy Volume: Watch For Potential Pullback

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $376.55 to a high of $396.00. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high...

REGN : 381.17 (+0.70%)
Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Global Blood Therapeutics

NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial...

REGN : 381.17 (+0.70%)
Detailed Research: Economic Perspectives on TESARO, Regeneron Pharmaceuticals, Pool, Zebra Technologies, Cadence Design, and TherapeuticsMD -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TESARO, Inc. (NASDAQ:TSRO),...

POOL : 146.84 (-2.71%)
CDNS : 43.22 (-2.02%)
TSRO : 73.69 (-1.07%)
REGN : 381.17 (+0.70%)
TXMD : 3.87 (-4.68%)
ZBRA : 171.89 (-0.52%)
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 mg or more of REGN1979

REGN : 381.17 (+0.70%)
Galapagos' Osteoarthritis Candidate Gets Fast Track Status

Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.

TEVA : 18.46 (-2.94%)
REGN : 381.17 (+0.70%)
GLPG : 104.12 (-3.14%)
PFE : 43.80 (-1.73%)
Watch for Regeneron Pharm to Potentially Pullback After Gaining 1.25% Yesterday

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $340.20 to a high of $349.63. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high...

REGN : 381.17 (+0.70%)
Glaxo Seeks Label Expansion of Nucala in Pediatric Patients

Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.

JNJ : 133.00 (-10.04%)
REGN : 381.17 (+0.70%)
GSK : 37.61 (-0.87%)
SNY : 44.05 (-1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 390.26
1st Resistance Point 385.71
Last Price 381.17
1st Support Level 377.81
2nd Support Level 374.46

See More

52-Week High 416.49
Last Price 381.17
Fibonacci 61.8% 365.07
Fibonacci 50% 349.19
Fibonacci 38.2% 333.31
52-Week Low 281.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar